We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Quidel (QDEL) Gains As Market Dips: What You Should Know
Read MoreHide Full Article
Quidel (QDEL - Free Report) closed at $198.03 in the latest trading session, marking a +0.05% move from the prior day. This move outpaced the S&P 500's daily loss of 0.38%. At the same time, the Dow lost 0.22%, and the tech-heavy Nasdaq lost 0.12%.
Prior to today's trading, shares of the medical diagnostics company had gained 2.49% over the past month. This has outpaced the Medical sector's gain of 2.06% and lagged the S&P 500's gain of 4.12% in that time.
Wall Street will be looking for positivity from QDEL as it approaches its next earnings report date. On that day, QDEL is projected to report earnings of $10.12 per share, which would represent year-over-year growth of 912%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $806.95 million, up 430.26% from the year-ago period.
It is also important to note the recent changes to analyst estimates for QDEL. These revisions help to show the ever-changing nature of near-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Our research shows that these estimate changes are directly correlated with near-term stock prices. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. The Zacks Consensus EPS estimate has moved 7.49% higher within the past month. QDEL is holding a Zacks Rank of #2 (Buy) right now.
Valuation is also important, so investors should note that QDEL has a Forward P/E ratio of 4.78 right now. This valuation marks a discount compared to its industry's average Forward P/E of 28.32.
Investors should also note that QDEL has a PEG ratio of 0.19 right now. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. Medical - Products stocks are, on average, holding a PEG ratio of 3.07 based on yesterday's closing prices.
The Medical - Products industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 205, which puts it in the bottom 20% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Quidel (QDEL) Gains As Market Dips: What You Should Know
Quidel (QDEL - Free Report) closed at $198.03 in the latest trading session, marking a +0.05% move from the prior day. This move outpaced the S&P 500's daily loss of 0.38%. At the same time, the Dow lost 0.22%, and the tech-heavy Nasdaq lost 0.12%.
Prior to today's trading, shares of the medical diagnostics company had gained 2.49% over the past month. This has outpaced the Medical sector's gain of 2.06% and lagged the S&P 500's gain of 4.12% in that time.
Wall Street will be looking for positivity from QDEL as it approaches its next earnings report date. On that day, QDEL is projected to report earnings of $10.12 per share, which would represent year-over-year growth of 912%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $806.95 million, up 430.26% from the year-ago period.
It is also important to note the recent changes to analyst estimates for QDEL. These revisions help to show the ever-changing nature of near-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Our research shows that these estimate changes are directly correlated with near-term stock prices. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. The Zacks Consensus EPS estimate has moved 7.49% higher within the past month. QDEL is holding a Zacks Rank of #2 (Buy) right now.
Valuation is also important, so investors should note that QDEL has a Forward P/E ratio of 4.78 right now. This valuation marks a discount compared to its industry's average Forward P/E of 28.32.
Investors should also note that QDEL has a PEG ratio of 0.19 right now. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. Medical - Products stocks are, on average, holding a PEG ratio of 3.07 based on yesterday's closing prices.
The Medical - Products industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 205, which puts it in the bottom 20% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.